Abstract
Background
This study aims at reviewing the use of the two SGLT2 inhibitors, dapagliflozin and empagliflozin, in a local hospital, Caritas Medical Centre, in terms of efficacy and safety.
Methods
This study was a retrospective, single-centered review carried out in Caritas Medical Centre. 143 adult patients who were prescribed with one of the two SGLT2 inhibitors available in CMC, between 1 Mar 2021 and 1 Mar 2022 were included in the study. The inclusive study duration were 12 months pre- and post- SGLT2 inhibitor initiation.
Results
The mean change in HbA1c level was a 13.25% and 9.04% decrease after the initiation of dapagliflozin and empagliflozin respectively (P0.05). Both post-dapagliflozin initiation period and post-empagliflozin had a significantly lower number of heart failure-related hospitalization per patient than pre-drug initiation period (P
Conclusions
Both dapagliflozin and empagliflozin were effective in reducing HbA1c levels in Chinese patients with type 2 diabetes and had a similar safety profile in terms of the risk of acute kidney injury. The cardiovascular benefit of SGLT2 inhibitors in reducing heart failure-related hospitalizations in patients diagnosed with both diabetes and heart failure is also demonstrated.
Recommended Citation
Wong Chi Ieong, A Retrospective Review on the Use of Dapagliflozin and Empagliflozin in Patients with Type 2 Diabetes with or without Heart Failure: A Local Hospital Data Journal of the Hong Kong College of Cardiology 2025;31(6) https://doi.org/10.55503/2790-6744.1547
Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License.